SELLAS Life Sciences (SLS) Total Non-Current Liabilities (2010 - 2022)
SELLAS Life Sciences (SLS) reported Total Non-Current Liabilities of $16.1 million for Q4 2022, up 185.72% year-over-year from $5.6 million in Q4 2021, and up 21.6% on a QoQ basis from $13.2 million in Q3 2022.
SELLAS Life Sciences (SLS) has 13 years of Total Non-Current Liabilities data on file, last reported at $16.1 million in Q4 2022.
- Quarterly Total Non-Current Liabilities rose 185.72% year-over-year to $16.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $16.1 million (up 185.72% YoY) and the FY2022 annual result came in at $16.1 million, up 185.72% from the prior year.
- Total Non-Current Liabilities advanced to $16.1 million in Q4 2022 per SLS's latest filing, from $13.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $30.1 million in Q1 2018 and bottomed at $3.9 million in Q1 2020.
- The 5-year median for Total Non-Current Liabilities is $7.2 million (2019), against an average of $10.9 million.
- The widest annual swing landed in 2019, when Total Non-Current Liabilities plunged 79.9%; it then surged 185.72% in 2022.
- Tracing SLS's Total Non-Current Liabilities over 5 years: stood at $7.3 million in 2018, then retreated by 23.69% to $5.6 million in 2019, then jumped by 140.1% to $13.5 million in 2020, then slumped by 58.14% to $5.6 million in 2021, then jumped by 185.72% to $16.1 million in 2022.
- Per Business Quant, the three latest SLS Total Non-Current Liabilities figures stand at $16.1 million (Q4 2022), $13.2 million (Q3 2022), and $13.0 million (Q2 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 16.09 Mn |
| Sep 30, 2022 | 13.23 Mn |
| Jun 30, 2022 | 12.97 Mn |
| Mar 31, 2022 | 17.11 Mn |
| Dec 31, 2021 | 5.63 Mn |
| Sep 30, 2021 | 6.31 Mn |
| Jun 30, 2021 | 5.31 Mn |
| Mar 31, 2021 | 7.07 Mn |
| Dec 31, 2020 | 13.46 Mn |
| Sep 30, 2020 | 5.38 Mn |
| Jun 30, 2020 | 5.54 Mn |
| Mar 31, 2020 | 3.91 Mn |
| Dec 31, 2019 | 5.60 Mn |
| Sep 30, 2019 | 6.01 Mn |
| Jun 30, 2019 | 5.89 Mn |
| Mar 31, 2019 | 7.26 Mn |
| Dec 31, 2018 | 7.34 Mn |
| Sep 30, 2018 | 14.69 Mn |
| Jun 30, 2018 | 29.30 Mn |
| Mar 31, 2018 | 30.10 Mn |
| Dec 31, 2017 | 30.16 Mn |
| Sep 30, 2017 | 33.68 Mn |
| Jun 30, 2017 | 40.20 Mn |
| Mar 31, 2017 | 41.93 Mn |
| Dec 31, 2016 | 10.32 Mn |
| Sep 30, 2016 | 47.96 Mn |
| Jun 30, 2016 | 52.64 Mn |
| Mar 31, 2016 | 47.64 Mn |
| Dec 31, 2015 | 62.49 Mn |
| Sep 30, 2015 | 43.67 Mn |
| Jun 30, 2015 | 45.71 Mn |
| Mar 31, 2015 | 42.55 Mn |
| Dec 31, 2014 | 36.78 Mn |
| Sep 30, 2014 | 41.75 Mn |
| Jun 30, 2014 | 44.49 Mn |
| Mar 31, 2014 | 38.80 Mn |
| Dec 31, 2013 | 75.27 Mn |
| Sep 30, 2013 | 50.18 Mn |
| Jun 30, 2013 | 40.24 Mn |
| Mar 31, 2013 | 31.48 Mn |
| Dec 31, 2012 | 21.02 Mn |
| Sep 30, 2012 | 15.16 Mn |
| Mar 31, 2012 | 33.48 Mn |
| Dec 31, 2011 | 16.29 Mn |
| Sep 30, 2011 | 21.48 Mn |
| Jun 30, 2011 | 19.56 Mn |
| Dec 31, 2010 | 5.05 Mn |